🇺🇸 Cross linking in United States

FDA authorised Cross linking on 15 April 2016

Marketing authorisations

FDA — authorised 15 April 2016

  • Application: NDA203324
  • Marketing authorisation holder: GLAUKOS
  • Status: supplemented

FDA — authorised 17 October 2025

  • Application: NDA219910
  • Marketing authorisation holder: GLAUKOS
  • Status: approved

FDA

  • Status: approved

Cross linking in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Cross linking approved in United States?

Yes. FDA authorised it on 15 April 2016; FDA authorised it on 17 October 2025; FDA has authorised it.

Who is the marketing authorisation holder for Cross linking in United States?

GLAUKOS holds the US marketing authorisation.